Skip to main content
. 2022 Dec 23;37(11):2320–2326. doi: 10.1038/s41433-022-02342-6

Fig. 1. Study designs.

Fig. 1

Study designs and patient disposition, NOVATIVE (A) and VEKTIS (B) trials BID, twice daily; CsA CE, cyclosporine A cationic ophthalmic emulsion; QID, 4 times daily.